[go: up one dir, main page]

BR0013113A - Piridazinas substituìdas e piridazinas fundidas com atividade inibidora da angiogênese - Google Patents

Piridazinas substituìdas e piridazinas fundidas com atividade inibidora da angiogênese

Info

Publication number
BR0013113A
BR0013113A BR0013113-0A BR0013113A BR0013113A BR 0013113 A BR0013113 A BR 0013113A BR 0013113 A BR0013113 A BR 0013113A BR 0013113 A BR0013113 A BR 0013113A
Authority
BR
Brazil
Prior art keywords
pyridazines
substituted
fused
angiogenesis
inhibiting activity
Prior art date
Application number
BR0013113-0A
Other languages
English (en)
Inventor
Jacques P Dumas
Holia N Hatoum-Mokdad
Teddy Kite Joe
Harold C E Kluender
Wendy Lee
Dhanapalan Nagarathnam
Robert N Sibley
Ning Su
Stephen James Boyer
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of BR0013113A publication Critical patent/BR0013113A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Patente de Invenção: "PIRIDAZINAS SUBSTITUìDAS E PIRIDAZINAS FUNDIDAS COM ATIVIDADE INIBIDORA DA ANGIOGêNESE". Piridazinas substituídas e fundidas tendo atividade de inibição da angiogênese e fórmula estrutural generalizada (I) em que o anel contendo A, B, D, E e L é um heterociclo contendo nitrogênio; grupos X e Y podem ser qualquer um de uma variedade de unidades de articulação definidas; R^ 1^ e R^ 2^ podem ser substituintes independentes definidos ouo juntos podem ser uma ponte de definição do anel; o anel J pode ser um grupo de arila, piridila ou cicloalquila; e os grupos G podem ser qualquer um de uma variedade de substituintes definidos. As composições farmacêuticas contendo estes materiais, e métodos de tratamento de um mamífero tendo uma condição caracterizada por angiogênese anormal ou processos de hipermeabilidade usando estes materiais são também apresentados.
BR0013113-0A 1999-08-10 2000-08-08 Piridazinas substituìdas e piridazinas fundidas com atividade inibidora da angiogênese BR0013113A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37132299A 1999-08-10 1999-08-10
PCT/US2000/021579 WO2001010859A1 (en) 1999-08-10 2000-08-08 Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity

Publications (1)

Publication Number Publication Date
BR0013113A true BR0013113A (pt) 2002-04-30

Family

ID=23463486

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0013113-0A BR0013113A (pt) 1999-08-10 2000-08-08 Piridazinas substituìdas e piridazinas fundidas com atividade inibidora da angiogênese

Country Status (19)

Country Link
EP (1) EP1208096B1 (pt)
JP (1) JP2003506447A (pt)
KR (1) KR20020019969A (pt)
CN (1) CN1378543A (pt)
AR (1) AR025068A1 (pt)
AT (1) ATE265448T1 (pt)
AU (1) AU775237B2 (pt)
BR (1) BR0013113A (pt)
CA (1) CA2381621A1 (pt)
CO (1) CO5180637A1 (pt)
DE (1) DE60010280T2 (pt)
ES (1) ES2219382T3 (pt)
IL (1) IL147885A0 (pt)
MX (1) MXPA02001324A (pt)
NO (1) NO20020569L (pt)
NZ (1) NZ517087A (pt)
PE (1) PE20010494A1 (pt)
WO (1) WO2001010859A1 (pt)
ZA (1) ZA200200691B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689883B1 (en) 1999-09-28 2004-02-10 Bayer Pharmaceuticals Corporation Substituted pyridines and pyridazines with angiogenesis inhibiting activity
CO5200835A1 (es) * 1999-09-28 2002-09-27 Bayer Corp Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis
US7977333B2 (en) 2000-04-20 2011-07-12 Bayer Healthcare Llc Substituted pyridines and pyridazines with angiogenesis inhibiting activity
GB0111078D0 (en) 2001-05-04 2001-06-27 Novartis Ag Organic compounds
SI1427420T1 (sl) * 2001-09-12 2006-12-31 Novartis Ag Uporaba kombinacije, ki vsebuje 4-piridilmetilftalazine za zdravljenje raka
MXPA04005561A (es) * 2001-12-21 2004-12-06 Bayer Pharmaceuticals Corp Terapias de combinacion anti-angiogenesis que comprenden derivados de piridazina o piridina.
US7015227B2 (en) 2002-06-21 2006-03-21 Cgi Pharmaceuticals, Inc. Certain amino-substituted monocycles as kinase modulators
WO2004028542A1 (en) * 2002-09-24 2004-04-08 Novartis Ag Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes
US20060058313A1 (en) * 2002-11-12 2006-03-16 Hohneker John A Treatment of mesothelioma
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
EP2137177B1 (en) 2007-04-05 2014-05-07 Amgen, Inc Aurora kinase modulators and method of use
PL2167549T3 (pl) 2007-06-19 2013-03-29 Rynel Inc Materiały zawierające cząstki polimeru rozpuszczalnego w wodzie oraz sposoby ich wytwarzania i stosowania
MX2010010151A (es) 2008-03-20 2010-10-25 Amgen Inc Moduladores de cinasa aurora y metodo de uso.
AU2009279760B2 (en) * 2008-08-04 2012-07-12 Amgen Inc. Aurora kinase modulators and methods of use
US9126935B2 (en) 2008-08-14 2015-09-08 Amgen Inc. Aurora kinase modulators and methods of use
JP2024505256A (ja) * 2021-01-28 2024-02-05 ユニバーシティ オブ フロリダ リサーチファウンデーション インコーポレイティッド 神経変性、変性及び代謝性障害の処置のための化合物並びにその使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
JPH03106875A (ja) * 1989-09-20 1991-05-07 Morishita Pharmaceut Co Ltd １―（３―ピリジルメチル）フタラジン誘導体
JPH0673022A (ja) * 1992-08-27 1994-03-15 Kumiai Chem Ind Co Ltd ピリミジンまたはトリアジン誘導体及び除草剤
HU219864B (hu) * 1994-08-09 2001-08-28 Eisai Co., Ltd. cGMP-PDE inhibitor kondenzált piridazinszármazékok és alkalmazásuk
JP3919835B2 (ja) * 1994-08-09 2007-05-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 縮合ピリダジン系化合物
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
DE60028740T2 (de) * 1999-03-30 2007-05-24 Novartis Ag Phthalazinderivate zur behandlung von entzündlichen erkrankungen

Also Published As

Publication number Publication date
NO20020569D0 (no) 2002-02-05
MXPA02001324A (es) 2002-07-22
EP1208096A1 (en) 2002-05-29
ES2219382T3 (es) 2004-12-01
DE60010280T2 (de) 2009-10-15
AU775237B2 (en) 2004-07-22
NO20020569L (no) 2002-04-10
IL147885A0 (en) 2002-08-14
WO2001010859A1 (en) 2001-02-15
ATE265448T1 (de) 2004-05-15
JP2003506447A (ja) 2003-02-18
AR025068A1 (es) 2002-11-06
KR20020019969A (ko) 2002-03-13
CO5180637A1 (es) 2002-07-30
CN1378543A (zh) 2002-11-06
ZA200200691B (en) 2003-10-29
CA2381621A1 (en) 2001-02-15
NZ517087A (en) 2004-05-28
AU6895400A (en) 2001-03-05
DE60010280D1 (de) 2004-06-03
EP1208096B1 (en) 2004-04-28
PE20010494A1 (es) 2001-06-27

Similar Documents

Publication Publication Date Title
BR0013113A (pt) Piridazinas substituìdas e piridazinas fundidas com atividade inibidora da angiogênese
BRPI0014382B8 (pt) piridinas e piridazinas substituídas com atividade de inibição de angiogênese bem como composições farmacêuticas compreendendo os mesmos
BR9810137A (pt) Composto, composição farmacêutica e método de tratamento ou prevenção de uma desordem tromoboembólica
WO2001019798A3 (en) Inhibitors of factor xa
WO2001019788A3 (en) BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
WO2000071510A3 (en) INHIBITORS OF FACTOR Xa
NO953967L (no) Indolderivater som 5-HT1A og/eller 5-HT2 ligander
BR9803497A (pt) Compostos, composições farmacêuticas, e processos para preparar os compostos e as composições e para tratar distúrbio do sistema nervoso central.
FR2674856B1 (fr) Nouveaux antihistaminiques non sedatifs, derives de benzimidazole, leur procede de preparation et leur utilisation en tant que medicaments.
DE69118198D1 (de) Substituierte tetrahydropyridine und hydroxypiperidine als mittel zur behandlung des zentralen nervensystems
ES2196308T3 (es) Derivado de 2-cianoiminoimidazol que inhiben la pde iv.
DE69433148D1 (de) Tricyclische kondensierte heterocyclische Verbindungen zur Behandlung von seniler Demenz
BR9811557A (pt) Derivados do 2-)4-aril ou heteroaril-piperazin-1-ilmetil)-1h-indol
NO180780C (no) Pyridonkarboksylsyrederivat
DK0450420T3 (da) Heterocyclisk substituerede dihydropyridiner, fremgangsmåde til deres fremstilling og deres anvendelse i lægemidler
NO975681L (no) Benzisoxazol- og indazol-derivater som antipsykotiske midler
NO923686L (no) Substituerte pyridinylamino-1h-indoler, 1h-indazoler, 2h-indazoler, benzo(b)-thiofener og 1,2-benzisotiazoler, en fremgangsmaate for deres fremstilling og deres anvendelse som legemidler
RU93045711A (ru) Нейролептические пергидро-1h-пиридо(1,2-a)пиразины, способ их получения, фармацевтическая композиция, способ лечения
BR9814188A (pt) "agonistas de 5-ht1f"
FI964436A0 (fi) Uudet hydroksiimijohdannaiset, niitä sisältävät farmaseuttiset koostumukset sekä menetelmä niiden valmistamiseksi
ATE244258T1 (de) Halo-derivate von 9-deoxo-9a-aza-9a- homerythromycin a
CA2334012A1 (en) 2-aminopyridines containing fused ring substituents as nitric oxide synthase inhibitors
BR0010673A (pt) Compostos substituìdos de benzolactamas
DK164057C (da) Oe5,6aa-cis-1,3-oxathianderivater og fremgangsmaade til deres fremstilling og farmaceutisk middel indeholdende et saadant derivat
ATE190316T1 (de) Peptid-aldehydderivate als antikoagulierende mittel

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A, 8A E 9A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009.